284 related articles for article (PubMed ID: 29866874)
1. Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an
de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866874
[TBL] [Abstract][Full Text] [Related]
2. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
Kim S; Louie A; Drusano GL; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Peloquin CA; Scanga CA; Yamada W; Neely M; Schmidt S
Int J Antimicrob Agents; 2022 Feb; 59(2):106509. PubMed ID: 34958863
[TBL] [Abstract][Full Text] [Related]
4. Effect of Moxifloxacin plus Pretomanid against
de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397058
[TBL] [Abstract][Full Text] [Related]
5. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Yang JS; Kim KJ; Choi H; Lee SH
Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
[TBL] [Abstract][Full Text] [Related]
6. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.
Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF
Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646
[TBL] [Abstract][Full Text] [Related]
7.
Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
[TBL] [Abstract][Full Text] [Related]
8. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition.
Yao C; Guo H; Li Q; Zhang X; Shang Y; Li T; Wang Y; Xue Z; Wang L; Li L; Pang Y
Antimicrob Resist Infect Control; 2021 Aug; 10(1):126. PubMed ID: 34446095
[TBL] [Abstract][Full Text] [Related]
10. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants.
Ismail N; Omar SV; Ismail NA; Peters RPH
J Microbiol Methods; 2018 Oct; 153():1-9. PubMed ID: 30165087
[TBL] [Abstract][Full Text] [Related]
11. Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region.
Lopez B; Siqueira de Oliveira R; Pinhata JMW; Chimara E; Pacheco Ascencio E; Puyén Guerra ZM; Wainmayer I; Simboli N; Del Granado M; Palomino JC; Ritacco V; Martin A
J Antimicrob Chemother; 2019 Feb; 74(2):373-379. PubMed ID: 30358851
[TBL] [Abstract][Full Text] [Related]
12. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
Zimenkov DV; Nosova EY; Kulagina EV; Antonova OV; Arslanbaeva LR; Isakova AI; Krylova LY; Peretokina IV; Makarova MV; Safonova SG; Borisov SE; Gryadunov DA
J Antimicrob Chemother; 2017 Jul; 72(7):1901-1906. PubMed ID: 28387862
[TBL] [Abstract][Full Text] [Related]
13. Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model.
Drusano GL; Myrick J; Maynard M; Nole J; Duncanson B; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Louie A
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866864
[TBL] [Abstract][Full Text] [Related]
14. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
Tasneen R; Betoudji F; Tyagi S; Li SY; Williams K; Converse PJ; Dartois V; Yang T; Mendel CM; Mdluli KE; Nuermberger EL
Antimicrob Agents Chemother; 2016 Jan; 60(1):270-7. PubMed ID: 26503656
[TBL] [Abstract][Full Text] [Related]
15. Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.
Rancoita PMV; Cugnata F; Gibertoni Cruz AL; Borroni E; Hoosdally SJ; Walker TM; Grazian C; Davies TJ; Peto TEA; Crook DW; Fowler PW; Cirillo DM;
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941636
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models.
Liu H; Zhu H; Fu L; Zhang W; Chen X; Wang B; Guo S; Ding Y; Wang N; Li D; Lu Y
Antimicrob Agents Chemother; 2023 Feb; 67(2):e0139922. PubMed ID: 36622240
[TBL] [Abstract][Full Text] [Related]
17. Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates.
Zou L; Liu M; Wang Y; Lu J; Pang Y
Tuberculosis (Edinb); 2015 Dec; 95(6):839-842. PubMed ID: 26395151
[TBL] [Abstract][Full Text] [Related]
18. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
[TBL] [Abstract][Full Text] [Related]
20. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
